{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.8","spread":"62.8","value":"60.1"},{"groupId":"OG001","lowerLimit":"54.9","spread":"54.9","value":"49.7"},{"groupId":"OG002","lowerLimit":"90.1","spread":"90.1","value":"76.9"},{"groupId":"OG003","lowerLimit":"118","spread":"118","value":"96.3"},{"groupId":"OG004","lowerLimit":"55.1","spread":"55.1","value":"53.4"},{"groupId":"OG005","lowerLimit":"129","spread":"129","value":"109"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with RR MM and/or NHL received 80 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG000","title":"Part 1a: 80 mg AMG 397"},{"description":"Participants with RR MM and/or NHL received 160 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG001","title":"Part 1a: 160 mg AMG 397"},{"description":"Participants with RR MM received 320 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG002","title":"Part 1a: 320 mg AMG 397"},{"description":"Participants with RR AML received 80 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG003","title":"Part 1b: 80 mg AMG 397"},{"description":"Participants with RR AML received 160 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG004","title":"Part 1b: 160 mg AMG 397"},{"description":"Participants with RR AML received 320 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG005","title":"Part 1b: 320 mg AMG 397"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK Analysis Set: All participants who received at least 1 dose of AMG 397 and had at least 1 PK sample collected.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (cycle = 28 days): Predose, 3, 5, & 8 hours postdose on days 1 (12 hours postdose on Day 1 only), 8 & 15, predose & 8 hours postdose on Day 22 & days 2, 3, 4, 9, 16, 17, 18 & 23; Cycles 2, 3 & 4 (cycle = 28 days): Predose on days 2, 8, 15 & 22","title":"Half-life (t1/2) of AMG 397","type":"SECONDARY","unitOfMeasure":"hours"}